[go: up one dir, main page]

EA200870292A1 - Соединения на основе имидазола, композиции, содержащие их, и способы их применения - Google Patents

Соединения на основе имидазола, композиции, содержащие их, и способы их применения

Info

Publication number
EA200870292A1
EA200870292A1 EA200870292A EA200870292A EA200870292A1 EA 200870292 A1 EA200870292 A1 EA 200870292A1 EA 200870292 A EA200870292 A EA 200870292A EA 200870292 A EA200870292 A EA 200870292A EA 200870292 A1 EA200870292 A1 EA 200870292A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions containing
imidazol
application
compounds based
Prior art date
Application number
EA200870292A
Other languages
English (en)
Other versions
EA015783B1 (ru
Inventor
Дэвид Дж. Оджери
Джеффри Багданофф
Лакмал У. Ботеджу
Кеннет Г. Карсон
Теодор К. Джессоп
Дэвид С. Кимболл
Original Assignee
Лексикон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лексикон Фармасьютикалз, Инк. filed Critical Лексикон Фармасьютикалз, Инк.
Publication of EA200870292A1 publication Critical patent/EA200870292A1/ru
Publication of EA015783B1 publication Critical patent/EA015783B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Раскрыты соединения имидазола, композиции, содержащие их, и способы их применения для лечения, предупреждения и контролирования воспалительных и аутоиммунных заболеваний и расстройств. Конкретные соединения имеют формулу (I).
EA200870292A 2006-02-24 2007-02-21 Производные имидазола, композиции и их применение в терапии EA015783B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77647306P 2006-02-24 2006-02-24
US81522106P 2006-06-20 2006-06-20
US11/698,253 US7649098B2 (en) 2006-02-24 2007-01-25 Imidazole-based compounds, compositions comprising them and methods of their use
PCT/US2007/004648 WO2007100617A2 (en) 2006-02-24 2007-02-21 Imidazole-based compounds, compositions comprising them and methods of their use

Publications (2)

Publication Number Publication Date
EA200870292A1 true EA200870292A1 (ru) 2009-02-27
EA015783B1 EA015783B1 (ru) 2011-12-30

Family

ID=38320192

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870292A EA015783B1 (ru) 2006-02-24 2007-02-21 Производные имидазола, композиции и их применение в терапии

Country Status (20)

Country Link
US (3) US7649098B2 (ru)
EP (2) EP2090334B1 (ru)
JP (1) JP5153655B2 (ru)
KR (1) KR20080096570A (ru)
AU (1) AU2007221265B2 (ru)
BR (1) BRPI0710076A2 (ru)
CA (1) CA2643021C (ru)
DK (1) DK2010501T3 (ru)
EA (1) EA015783B1 (ru)
EC (1) ECSP088692A (ru)
ES (1) ES2456673T3 (ru)
IL (1) IL193297A (ru)
MX (1) MX2008010772A (ru)
NO (1) NO20084024L (ru)
NZ (1) NZ570308A (ru)
PL (1) PL2010501T3 (ru)
PT (1) PT2010501E (ru)
SG (1) SG170024A1 (ru)
WO (1) WO2007100617A2 (ru)
ZA (1) ZA200806842B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2650907B1 (en) 2004-06-04 2024-10-23 The Board Of Trustees Of The University Of Illinois Methods and devices for fabricating and assembling printable semiconductor elements
TW200848029A (en) 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TWI412362B (zh) * 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
UY31013A1 (es) * 2007-04-12 2008-09-02 Lexicon Pharmaceuticals Inc Metodos para prepar compuestos basados en imidazol
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
MX2010010799A (es) * 2008-03-31 2011-03-25 Univ Columbia Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
TW201002698A (en) * 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
CN102131803A (zh) * 2008-06-18 2011-07-20 莱西肯医药有限公司 (1r，2s，3r)-1-(2-(异噁唑-3-基)-1h-咪唑-4-基)丁烷-1，2，3，4-四醇的固体形式及其使用方法
CA2730500C (en) 2008-07-23 2017-11-28 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
RS54970B1 (sr) 2008-08-27 2016-11-30 Arena Pharm Inc Supstituisani triciklični derivati kiselina kao s1p1 receptor agonisti korisni pri lečenju autoimunih i upalnih poremećaja
AR074061A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Inhibidores de s1p liasa para el tratamiento de la malaria cerebral y formulacion farmaceutica
AR074062A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
AU2010313521B2 (en) * 2009-10-26 2014-01-30 Lexicon Pharmaceuticals, Inc. Methods of preparing 1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011102404A1 (ja) 2010-02-18 2011-08-25 第一三共株式会社 イミダゾール誘導体
EP2542554B1 (en) 2010-03-03 2015-11-04 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
US9200309B2 (en) 2010-06-28 2015-12-01 Daiichi Sankyo Company, Limited Method for screening for S1P lyase inhibitors using cultured cells
JP5960138B2 (ja) * 2011-06-28 2016-08-02 第一三共株式会社 リン酸エステル誘導体
WO2013049272A2 (en) 2011-09-29 2013-04-04 Theraceutix, Llc Composition and method for treatment of symptoms associated with various skin conditions
TR201302590A2 (tr) * 2013-03-04 2014-09-22 S Gueniz Kuecuekguezel Diflunisalden hareketle yeni bileşiklerin sentezi.
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11612595B2 (en) 2017-05-16 2023-03-28 Generos Biopharma Ltd. Compositions and methods for treating rheumatoid arthritis
EP3443986A1 (en) * 2017-08-17 2019-02-20 AC BioScience Enhancement of chemotherapy efficiency by sphingosine-1-phosphate
MX2020013157A (es) 2018-06-06 2021-04-29 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
WO2025027051A1 (en) * 2023-07-31 2025-02-06 Ab Science Sphingosine-1-phosphate lyase inhibitors for use in the treament of neurodegenerative diseases

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788548A (fr) * 1971-09-10 1973-03-08 Bayer Ag Nouveaux acides 2-imidazolyl-carbonyl-benzoiques, leurs esters et leur sels, leur procede de preparation et leur application comme regulateursde croissance des vegetaux
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
US4614662A (en) * 1985-08-26 1986-09-30 D. D. Williamson & Co., Inc. Fast cook-continuous process for production of ammonia caramel color
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH06510781A (ja) 1991-09-26 1994-12-01 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ムピロシン関連の抗菌性、抗マイコプラスマ性化合物
GB9201391D0 (en) 1992-01-22 1992-03-11 Smithkline Beecham Plc Method of treatment
DE4205081A1 (de) 1992-02-20 1993-08-26 Bayer Ag 1-acyloxy-2-azolyl-ethane
US5324840A (en) * 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5519040A (en) * 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
SE9401965D0 (sv) * 1994-06-07 1994-06-07 Astra Ab New compounds
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
AU3201095A (en) * 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
FI971234A7 (fi) * 1994-09-26 1997-05-23 Shionogi & Co Imidatsolijohdannainen
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
FR2743366B1 (fr) * 1996-01-10 1998-02-06 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant
WO1997046543A1 (en) 1996-05-31 1997-12-11 The University Of Wollongong Acetyl derivatives of thiazoles and analogues
US6139833A (en) 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US6207371B1 (en) 1996-10-04 2001-03-27 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6136566A (en) 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6423527B1 (en) * 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
KR100882544B1 (ko) * 1999-05-24 2009-02-12 미쓰비시 타나베 파마 코퍼레이션 페녹시프로필아민 화합물
JP4156807B2 (ja) 1999-06-01 2008-09-24 エラン ファーマ インターナショナル，リミティド 小型ミル及びその方法
DE10025672A1 (de) 2000-05-24 2001-11-29 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
AU2002239721C1 (en) * 2000-12-22 2008-04-24 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
DE10111936C1 (de) * 2001-03-13 2002-10-02 Wella Ag N-Heteroarylmethyl-m-phenylendiamin-Derivate enthaltende Haarfärbemittel sowie neue N-Heteroarylmethyl-m-phenylendiamin-Derivate
PT1392441E (pt) 2001-06-05 2008-09-30 Elan Pharma Int Ltd Sistema e método para trituração de materiais
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
DE10130145A1 (de) * 2001-06-22 2003-01-02 Wella Ag Kationische Farbstoffe, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Färbemittel
WO2003016291A1 (fr) * 2001-08-10 2003-02-27 Nippon Chemiphar Co., Ltd. Activateur du recepteur $g(d) sensible au proliferateur de peroxysome
CA2460345A1 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
US6692960B2 (en) * 2001-09-28 2004-02-17 Isis Pharmaceuticals, Inc. Antisense modulation of sphingosine-1-phosphate lyase expression
JP4878839B2 (ja) 2002-09-11 2012-02-15 エラン ファーマ インターナショナル，リミティド ゲル安定化ナノパーティクル活性物質組成物
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
JP2007515429A (ja) * 2003-12-19 2007-06-14 エリクシアー ファーマシューティカルズ， インコーポレイテッド 障害を治療する方法
WO2005072412A2 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
NZ549003A (en) * 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor
TW200848029A (en) * 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TWI412362B (zh) * 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders

Also Published As

Publication number Publication date
WO2007100617A3 (en) 2008-01-17
KR20080096570A (ko) 2008-10-30
ECSP088692A (es) 2008-11-27
SG170024A1 (en) 2011-04-29
CA2643021A1 (en) 2007-09-07
DK2010501T3 (da) 2014-06-30
US20100076030A1 (en) 2010-03-25
MX2008010772A (es) 2008-09-01
EP2090334A3 (en) 2009-09-23
EP2090334B1 (en) 2015-04-29
IL193297A (en) 2013-03-24
CA2643021C (en) 2015-04-07
US8404732B2 (en) 2013-03-26
EP2090334A2 (en) 2009-08-19
US7649098B2 (en) 2010-01-19
PT2010501E (pt) 2014-05-07
ZA200806842B (en) 2009-12-30
ES2456673T3 (es) 2014-04-23
NZ570308A (en) 2010-09-30
BRPI0710076A2 (pt) 2011-08-02
US8093267B2 (en) 2012-01-10
AU2007221265A1 (en) 2007-09-07
AU2007221265B2 (en) 2012-08-02
NO20084024L (no) 2008-11-06
JP2009527564A (ja) 2009-07-30
EP2010501B1 (en) 2014-04-02
US20130005775A1 (en) 2013-01-03
EA015783B1 (ru) 2011-12-30
PL2010501T3 (pl) 2014-09-30
IL193297A0 (en) 2009-08-03
JP5153655B2 (ja) 2013-02-27
EP2010501A2 (en) 2009-01-07
US20070208063A1 (en) 2007-09-06
WO2007100617A2 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
EA201170521A1 (ru) Новые соединения
EA200970818A1 (ru) Гетероциклические соединения, содержащие их композиции и способы их применения
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA201290305A1 (ru) Производные трициклического пиразоламина
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
NO20083568L (no) Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA200700225A1 (ru) Аналоги тетрапептида
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
NO20090624L (no) Forbindelser som modulerer CB2 receptoren
EA200802213A1 (ru) Способы лечения заболеваний крови
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EA201070238A1 (ru) Соединения пиримидина
NO20083690L (no) Hydantoin baserte kinase-inhibitorer
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM